Bioventus Inc. (NYSE:BVS) SVP Anthony D'adamio Sells 2,958 Shares

Bioventus Inc. (NYSE:BVS - Get Free Report) SVP Anthony D'adamio sold 2,958 shares of the firm's stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $7.57, for a total transaction of $22,392.06. Following the sale, the senior vice president now owns 131,416 shares in the company, valued at approximately $994,819.12. This trade represents a 2.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Anthony D'adamio also recently made the following trade(s):

• On Tuesday, February 18th, Anthony D'adamio sold 4,380 shares of Bioventus stock. The stock was sold at an average price of $10.19, for a total value of $44,632.20.

Bioventus Trading Up 0.5 %

Shares of BVS traded up $0.04 during mid-day trading on Friday, reaching $7.82. The company had a trading volume of 323,591 shares, compared to its average volume of 446,547. The stock has a market cap of $640.80 million, a price-to-earnings ratio of -12.82 and a beta of 0.92. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The firm has a fifty day simple moving average of $9.29 and a 200-day simple moving average of $10.60. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group reaffirmed a "buy" rating and set a $15.00 price objective on shares of Bioventus in a research note on Monday, March 17th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Bioventus by 18.7% during the fourth quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company's stock worth $25,852,000 after acquiring an additional 388,174 shares during the last quarter. Driehaus Capital Management LLC increased its position in Bioventus by 33.7% during the 4th quarter. Driehaus Capital Management LLC now owns 1,119,855 shares of the company's stock worth $11,758,000 after purchasing an additional 282,341 shares in the last quarter. Geode Capital Management LLC raised its holdings in Bioventus by 7.5% in the third quarter. Geode Capital Management LLC now owns 940,496 shares of the company's stock valued at $11,241,000 after buying an additional 65,374 shares during the period. American Century Companies Inc. grew its stake in Bioventus by 38.7% during the fourth quarter. American Century Companies Inc. now owns 884,673 shares of the company's stock worth $9,289,000 after buying an additional 246,645 shares during the period. Finally, Nuveen Asset Management LLC boosted its position in Bioventus by 20.9% during the 4th quarter. Nuveen Asset Management LLC now owns 782,137 shares of the company's stock worth $8,212,000 after purchasing an additional 135,236 shares during the period. Institutional investors and hedge funds own 62.94% of the company's stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.